Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas

Edgar Ben-Josef, Asha George, William F. Regine, Ross Abrams, Meredith Morgan, Dafydd Thomas, Paul L. Schaefer, Thomas A. DiPetrillo, Mitchel Fromm, William Small, Samir Narayan, Kathryn Winter, Kent A. Griffith, Chandan Guha, Terence M. Williams

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Purpose: GSK3β is a protein kinase that can suppress a number of key oncoproteins. We have previously shown in preclinical models of pancreatic ductal adenocarcinoma (PDAC) that inhibition of GSK3β causes stabilization and nuclear translocation of b-catenin, poor differentiation, proliferation, and resistance to radiation. The objective of this study was to determine its utility as a biomarker of clinical outcomes. Experimental Design: Automated Quantitative Immunofluorescence Analysis (AQUA) of GSK3β was performed on a tissue microarray with samples from 163 patients treated on RTOG 9704. On the basis of findings in an exploratory cohort, GSK3β was analyzed as a categorical variable using its upper quartile (

Original languageEnglish (US)
Pages (from-to)5612-5618
Number of pages7
JournalClinical Cancer Research
Volume21
Issue number24
DOIs
StatePublished - Dec 15 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas'. Together they form a unique fingerprint.

  • Cite this

    Ben-Josef, E., George, A., Regine, W. F., Abrams, R., Morgan, M., Thomas, D., Schaefer, P. L., DiPetrillo, T. A., Fromm, M., Small, W., Narayan, S., Winter, K., Griffith, K. A., Guha, C., & Williams, T. M. (2015). Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas. Clinical Cancer Research, 21(24), 5612-5618. https://doi.org/10.1158/1078-0432.CCR-15-0789